Evidence map›Paper›PMID 39008896›Full record

ArticleInternational journal of epidemiology2024

Prospective evaluation of the relevance of Epstein-Barr virus antibodies for early detection of nasopharyngeal carcinoma in Chinese adults.

Ling Yang, Christiana Kartsonaki, Julia Simon, Pang Yao, Yu Guo, Jun Lv, Robin G Walters, Yiping Chen, Hannah Fry, Daniel Avery and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ling YangClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Christiana KartsonakiClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Julia SimonInfections and Cancer Epidemiology Division, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pang YaoClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Yu GuoNational Center for Cardiovascular Diseases, Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China.
Jun LvDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China.ORCID 0000-0001-7916-3870
Robin G WaltersClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Yiping ChenClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Hannah FryClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Daniel AveryClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Canqing YuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China.ORCID 0000-0002-0019-0014
Jianrong JinNCD Department, Wuzhong CDC, Suzhou, China.
Alexander J MentzerThe Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-4502-2209
Naomi AllenClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0003-1938-5038
Julia ButtInfections and Cancer Epidemiology Division, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-7738-8611
Michael HillClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-3861-6105
Liming LiDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China.ORCID 0000-0001-5873-7089
Iona Y MillwoodClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Tim WaterboerInfections and Cancer Epidemiology Division, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zhengming ChenClinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Funding

Cancer Research UK 29186China Kadoorie BiobankKadoorie Charitable Foundation, Hong KongMedical Research Council MC_UU_00017/1MRC Research MR/S014551/1National Natural Science Foundation of China 91843302UK Wellcome Trust 212946/Z/18/ZWellcome Trust
6 · The paper itself

Abstract

backgroundEpstein-Barr virus (EBV) is a major cause of nasopharyngeal carcinoma (NPC) and measurement of different EBV antibodies in blood may improve early detection of NPC. Prospective studies can help assess the roles of different EBV antibodies in predicting NPC risk over time.

methodsA case-cohort study within the prospective China Kadoorie Biobank of 512 715 adults from 10 (including two NPC endemic) areas included 295 incident NPC cases and 745 subcohort participants. A multiplex serology assay was used to quantify IgA and IgG antibodies against 16 EBV antigens in stored baseline plasma samples. Cox regression was used to estimate adjusted hazard ratios (HRs) for NPC and C-statistics to assess the discriminatory ability of EBV-markers, including two previously identified EBV-marker combinations, for predicting NPC.

resultsSero-positivity for 15 out of 16 EBV-markers was significantly associated with higher NPC risk. Both IgA and IgG antibodies against the same three EBV-markers showed the most extreme HRs, i.e. BGLF2 (IgA: 124.2 (95% CI: 63.3-243.9); IgG: 8.6 (5.5-13.5); LF2: [67.8 (30.0-153.1), 10.9 (7.2-16.4)]); and BFRF1: 26.1 (10.1-67.5), 6.1 (2.7-13.6). Use of a two-marker (i.e. LF2/BGLF2 IgG) and a four-marker (i.e. LF2/BGLF2 IgG and LF2/EA-D IgA) combinations yielded C-statistics of 0.85 and 0.84, respectively, which persisted for at least 5 years after sample collection in both endemic and non-endemic areas.

conclusionsIn Chinese adults, plasma EBV markers strongly predict NPC occurrence many years before clinical diagnosis. LF2 and BGLF2 IgG could identify NPC high-risk individuals to improve NPC early detection in community and clinical settings.

Indexed as

Antibodies, ViralEarly Detection of CancerEpstein-Barr Virus InfectionsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAdultAgedCase-Control StudiesChinaEast Asian PeopleFemaleHerpesvirus 4, HumanHumansImmunoglobulin AImmunoglobulin GMaleAntibodies, ViralImmunoglobulin AImmunoglobulin Gcase-cohort studyChinaearly detectionEpstein–Barr Virus (EBV)multiplex serology assayNasopharyngeal cancer

Identifiers

PMID39008896
PMCPMC11249388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.